Prof. Qiming Wang 王启鸣
Chief Physician, Professor
Department of Integrated Traditional Chinese and Western Medicine Oncology, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Refractory lung cancer and small cell lung cancer.
Dr. Wang is a Chief Physician, Professor, and PhD supervisor at Henan Cancer Hospital, serving as Deputy Director of Internal Medicine and Director of the Third Ward of Respiratory Medicine. A postdoctoral fellow at MD Anderson Cancer Center and visiting professor at Emory University, Dr. Wang focuses on refractory and small cell lung cancer. Roles include reviewer for 28 SCI journals and editorial board member for Annals of Translational Medicine.
Professional roles
- Member, Chinese Medical Association
- Council Member, Chinese Society of Clinical Oncology (CSCO)
- Chair, Lung Cancer Expert Committee, Henan Provincial Tumor Diagnosis and Treatment Quality Control Center
- Designated Chair, Oncology Branch, Henan Medical Association
Name order: in Chinese the family name comes first (Wang Qiming). Papers usually list the name as Qiming Wang or Wang Q.
Selected publications
182 papers on PubMed matched by name and affiliation; 50 as first or senior author since 2016. Most recent first- or senior-author papers:
- Lung Cancer, 2026 (senior author): Multi-omics liquid biopsy for leptomeningeal metastases in lung cancer: from molecular mechanisms to precision diagnosis and treatment. PubMed 42893629
- Eur J Cancer, 2026 (senior author): High-dose furmonertinib plus bevacizumab and intrathecal pemetrexed for EGFR-RAD51 fusion-positive lung adenocarcinoma with leptomeningeal metastasis: Insights from serial CSF ctDNA monitoring. PubMed 42600507
- Apoptosis, 2026 (senior author): DONSON links tumor-cell survival to MIF-associated macrophage remodeling in small cell lung cancer. PubMed 42791421
- Lung Cancer, 2026 (senior author): Development and validation of a risk-stratification model for individualized management of leptomeningeal metastases in EGFR- mutant NSCLC (LM-Index). PubMed 42501706
- iScience, 2026 (senior author): NPC2 suppresses osteolytic metastasis in lung adenocarcinoma via the AKT/mTOR pathway and tumor-osteoclast crosstalk. PubMed 41816293
- Chin J Cancer Res, 2026 (senior author): Chemotherapy-free regimen: Real-world efficacy and safety of anlotinib plus PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer. PubMed 41847186
- Cell Mol Biol Lett, 2025 (senior author): Ribosomal protein RPL7A modulates lung adenocarcinoma progression via circRANBP17-UPF1-mediated SIRT6 degradation. PubMed 41372808
- Clin Epigenetics, 2025 (senior author): Peripheral blood mononuclear cell DNA methylation biomarkers for prognostic stratification in Chinese lung adenocarcinoma: a genome-wide epigenetic profiling study. PubMed 41146333
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion